WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences:

BTIG Virtual Biotechnology Conference
Dates: August 5-6, 2024

2024 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 13, 2024

About Replimune 

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
This email address is being protected from spambots. You need JavaScript enabled to view it.